By Andrew Todd
Copyright brisbanetimes
Proteomics International Laboratories has received a milestone seal of approval for its industrial-scale Perth-based laboratory. The pivotal international certification will support the roll-out of the company’s precise yet simple diagnostic blood tests in Australia.
The internationally recognised ISO 15189 medical testing accreditation validates the company’s ability to deliver accurate and reliable clinical results, supporting the commercialisation of Proteomics’ cutting-edge “traffic light” system diagnostic portfolio.
That portfolio is expanding rapidly in four significant diagnostic fields. Proteomics recently launched its PromarkerD test for diabetic kidney disease and PromarkerEso test for oesophageal cancer.
After a rigorous audit of its Perth-based lab facilities, systems and processes, the precision medical technology company got the regulatory nod. The latest certification builds on its existing list of international medical accreditations, placing the company at the head of the pack of the world’s leading proteomics and protein-based testing services.
